The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans

[1]  N. Schork,et al.  Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC). , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Á. Gutiérrez-Dalmau,et al.  Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients , 2012, Drugs.

[3]  A. Israni,et al.  Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.

[4]  Ralph DiGaetano,et al.  Hypertension and Risk of Renal Cell Carcinoma Among White and Black Americans , 2011, Epidemiology.

[5]  V. D’Agati,et al.  APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[6]  Giulio Genovese,et al.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[7]  Ross Ward,et al.  United States Renal Data System , 2011 .

[8]  J. Mclaughlin,et al.  Renal cell cancer among African Americans: an epidemiologic review , 2011, BMC Cancer.

[9]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[10]  C. Nguyen,et al.  Racial disparities in urologic health care. , 2010, Journal of the National Medical Association.

[11]  A. Webster,et al.  The pattern of excess cancer in dialysis and transplantation. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  W. Chow,et al.  Contemporary Epidemiology of Renal Cell Cancer , 2008, Cancer journal.

[13]  J. Kaldor,et al.  Cancer incidence before and after kidney transplantation. , 2006, JAMA.

[14]  M. Joffe,et al.  Rates of completion of the medical evaluation for renal transplantation. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  V. Janout,et al.  Epidemiology and risk factors of kidney cancer. , 2004, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[16]  E. Geissler,et al.  PRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION , 2004, Transplantation.

[17]  R. Hayes,et al.  Cancer Causes & Control , 2004, Cancer Causes & Control.

[18]  P. Boyle,et al.  Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. , 2003, Journal of the American Society of Nephrology : JASN.

[19]  Keith C. Norris,et al.  The epidemiology of end-stage renal disease among African Americans. , 2002, The American journal of the medical sciences.

[20]  A. Heidland,et al.  Incidence and spectrum of dialysis-associated cancer in three continents. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  P. Boyle,et al.  Cancer in patients on dialysis for end-stage renal disease: an international collaborative study , 1999, The Lancet.

[22]  K F Rust,et al.  Variance estimation for complex surveys using replication techniques , 1996, Statistical methods in medical research.

[23]  W. McClellan,et al.  Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.